Global Peptic Ulcer Drugs Market By Drug Type (Proton Pump Inhibitors, Potassium-Competitive Acid Blocker, H2-Antagonists, Antacids, Antibiotics, and Ulcer protective), By Indication (Duodenal Ulcer, Gastric Ulcer, Gastroesophageal Reflux Disease, Gastritis, and Other Indications), By Distribution Channel, By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Report Overview

The Global Peptic Ulcer Drugs Market size is expected to be worth around USD 6.4 Billion by 2032 from USD 4.6 Billion in 2022, growing at a CAGR of 3.5% during the forecast period from 2023 to 2032.

The open sores developed in the stomach’s inside lining and the small intestine’s upper portion is called peptic ulcer. Generally, peptic ulcers are caused due to radiation therapy, inflammation, and frequent use of aspirins orally or parentally. If peptic ulcers are left untreated, they may lead to complications such as severe pain in the mid or upper-body parts, internal bleeding, weight loss, and severe blood loss, which needs hospitalization.

These complications are treated with peptic ulcer drugs, driving the demand for their availability and significantly increasing the market growth. The rising prevalence of peptic ulcers, especially in geriatric individuals, and the shifting of the consumer inclination towards different medications over invasive surgeries are the factors responsible for the growth of peptic ulcer drugs.

*Actual Numbers Might Vary In The Final Report

Key Takeaways

• Peptic Ulcer Overview: Peptic ulcers are painful sores that form on the mucosal linings of the stomach, small intestine, or esophagus and cause various symptoms including abdominal pain, heartburn and even bleeding in these organs.
• Etiology and Risk Factors for Peptic Ulcers: Peptic ulcers can be caused by factors like Helicobacter pylori infection, prolonged use of nonsteroidal anti-inflammatory drugs (NSAIDs), smoking cigarettes heavily consuming alcohol beverages or even stress.
• Drug Classes: Common medications prescribed to treat peptic ulcers include proton pump inhibitors (PPIs), H2-receptor antagonists, antacids, antibiotics (to eradicate H. pylori infection) and cytoprotective agents.
• Proton Pump Inhibitors (PPIs): PPIs are frequently prescribed to reduce stomach acid production, providing relief from symptoms while hastening ulcer healing.
• H2-Receptor Antagonists: H2-blockers work by decreasing stomach acid production. Their use helps alleviate symptoms while encouraging ulcer healing.
• Antacids: Antacids help neutralize stomach acid and can provide temporary relief of pain associated with peptic ulcers.

Type Analysis

Antibiotics accounted for a dominant segment of the global peptic ulcer drugs market in 2022

Based on drug type, the market for peptic ulcer drugs is segmented into proton pump inhibitors, potassium-competitive acid blockers, H2-antagonists, antacids, antibiotics, and ulcer protection. Among these drug types, the antibiotics segment is the most dominant, mainly used in the peptic ulcer drugs market. It held the largest revenue share of 39% % in 2022.

The leading cause behind peptic ulcers is the bacteria known as H.pyroli. Antibiotics stand for first-line therapy, which includes one PPI and two antibiotics. Therefore, this results in higher adoption of antibiotics, making it a dominant segment. Second in the treatment option is proton pump inhibitors which are expected to grow at a significant CAGR over the forecast period.

By Indication Analysis

In 2022, the duodenal ulcer segment accounted for holding the largest revenue share of the global market for peptic ulcer drugs

Based on indication, the global market for peptic ulcer drugs is divided into a duodenal ulcer, gastric ulcer, gastroesophageal reflux disease, gastritis, and other indications. The duodenal ulcer segment accounted for the largest market share in 2022 and is expected to continue its dominance during the forecast period. The rising prevalence of duodenal ulcers, increasing awareness, and therapeutic launches for its treatments are the factors predicted for this segment’s growth.

Moreover, the drugs for peptic ulcers are also effective in gastritis and gastroesophageal reflux disease, which is subjected to the further expansion of the market.

Distribution Channel Analysis

The hospital pharmacies dominated the peptic ulcer drugs market in 2022

The market is further classified by distribution channel into retail pharmacies, hospital pharmacies, and online pharmacies. The hospital pharmacies segment is estimated to hold a dominant market share over the forecast period. The larger availability of peptic ulcer drugs at hospital pharmacies is positively driving the growth of this segment. The rise in the diagnosis of peptic ulcer patients and frequent hospital visits to get effective treatment is the key factor supporting its dominance.

Additionally, the popularity of online pharmacies is increasing among most people. Its convenience and ease will likely propel the growth of the online pharmacies segment over the forecast period.

Moreover, retail pharmacies offer generic drugs for peptic ulcers, which are affordable compared to branded drugs. Additionally, the OTC drugs for sudden stomach upsets and complications regarding gastric problems are further driving the market growth.

Key Market Segments

Based on Drug Type

• Proton Pump Inhibitors
• Potassium-Competitive Acid Blocker (P-CAB)
• H2-Antagonists
• Antacids
• Antibiotics
• Ulcer protective

Based on Indication

• Duodenal Ulcer
• Gastric Ulcer
• GERD (Gastroesophageal Reflux Disease)
• Gastritis
• Other Indications

Based on Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Drivers

Rising prevalence of peptic ulcer to support the market growth

The rising prevalence of peptic ulcers worldwide largely influences the market for peptic ulcer drugs. An ulcer develops when the stomach acid damages the stomach’s protective lining. This acid leads to the stomach’s open sores, resulting in bleeding and causing severe and intolerable pain. Peptic ulcer manifests itself in several ways, including gastric ulcers. Drugs that aids in the reduction of gastric secretion, such as PPIs, H2 receptor antagonists, antibiotics against H. pylori infection, and acid-neutralization agents, such as antacid, are used to treat peptic ulcers.

However, these medicines are administered frequently in combination to acquire a greater effect. Moreover, the rising usage of NSAIDS is one of the major reasons causing peptic ulcers and thus leads to the increase in demand for peptic ulcer drugs.

Awareness about the peptic ulcer drugs and sedentary lifestyle of individuals to propel the market growth

Rising initiatives by private and public organizations to spread awareness about peptic ulcer complications is likely to expand the growth of the peptic ulcer drugs market. Moreover, the sedentary lifestyle of individuals having an addiction to smoking and high alcohol consumption, which are the most common causes of peptic ulcer, increases the demand for peptic ulcer drugs and is expected to result in market expansion. An increase in disposable income and a rising geriatric population are the key factors predicted to contribute to the market’s growth over the forecast period.

The market growth is likely to expand due to the rising initiatives by private and public organizations to spread awareness about peptic ulcer complications. Moreover, individuals with a sedentary lifestyle have the habits such as addiction to smoking and high alcohol consumption, some of the most common causes resulting in peptic ulcer. These factors significantly increase the demand for peptic ulcer drugs and are anticipated to drive market growth positively.

Restraints

Numerous ADRs associated with peptic ulcer drugs restrict the market growth

Despite the rising global prevalence of peptic ulcers, some factors are expected to limit the growth of the drug market. In Addition, ADRs associated with the usage of peptic ulcer drugs, such as the side effects of PPI, include the increased risk of gastroenteritis, nutritional deficiencies (vitamin B12, magnesium), bowel upset, and diarrhea.

The side effects associated with using anticholinergic drugs include dry mouth, urine retention, and constipation. Moreover, patent expiration and strict government regulations are responsible factors that are anticipated to restrict the growth of the global market for peptic ulcer drugs during the forecast period.

Opportunity

Increase in a strong pipeline of new drugs and increase in R&D activities to boost the market growth.

The increasing prevalence of peptic ulcers worldwide is propelling the major industry players to invest more in research & development activities. This involves launching a new drug for treating peptic ulcers, which will likely positively impact the peptic ulcer drug market.

Conducting clinical trials for investigational drugs to overcome the complications associated with the currently available drugs is another key factor expected to drive market growth during the forecast period.

Trends

Increasing adoption of OTC drugs to surge the market growth

A wide variety of OTC drugs are available for treating peptic ulcers in individuals. The approved OTC non-steroidal anti-inflammatory drugs allow faster and more affordable healthcare access, increasing their popularity and adoption among patients. Many peptic ulcer drugs, such as antacids, H2-receptor antagonists, antibiotics, and proton pump inhibitors, are available as OTC drugs. Many pharmaceutical companies are investing heavily in developing over-the-counter versions of peptic ulcer medications, which is anticipated to boost market expansion in the coming years.

Regional Analysis

North America held the maximum revenue share of the global market in 2022

Based on region, the global peptic ulcer drugs market is classified into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Among these regions, North America dominated the global peptic ulcer drugs market in 2022 with the largest revenue share of 43% and is expected to remain dominant over the forecast period. This is largely due to the surge in the use of (NSAIDs) such as aspirin and increasing awareness about the treatment options for peptic ulcers. These are major factors predicted to surge the growth of the peptic ulcer drugs market in North America.

Europe’s peptic ulcer drugs market holds the second-largest market share, owing to the easy availability of effective treatment options for peptic ulcers in this region.

The market for peptic ulcer drugs in Asia Pacific is anticipated to grow faster due to the development in healthcare infrastructure, the rising prevalence of peptic ulcers, and increasing awareness among the population. Latin America and, the Middle East & Africa are accounted to exhibit a lower growth rate due to the less awareness, unmet needs of healthcare, and a developing healthcare sector.

Key Regions

        North America

• • The US
  • Canada

        Western Europe

• • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe

         Eastern Europe

• • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe

         APAC

• • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC

         Latin America

• • Brazil
  • Colombia
  • Chile
  • Argentina
  • Mexico
  • Costa Rica
  • Rest of Latin America

         Middle East & Africa

• • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Key Players Analysis

Diverse & strong product portfolios, along with a well-organized distribution network worldwide, are the major factors attributable to the dominance of key players. These prominent players are actively involved in R&D activities resulting in strong regulatory approvals. Additionally, they are involved in strategic collaborations, partnerships, new product launches, mergers & acquisitions, significantly contributing to peptic ulcer drug market growth.

Below are some of the most prominent players in the global peptic ulcer drugs market

Market Key Players

• Abbott
• AstraZeneca plc
• Zydus Lifesciences Limited
• Boehringer Ingelheim International GmbH
• Novitium Pharma
• Yuhan Corporation
• Pfizer Inc.
• Pharmaking Co. Ltd.
• Viatris Inc.
• RedHill Biopharma Ltd.
• Novartis AG
• Other Key Players

Key Industry Developments

• In May 2020, the USFDA approved the three-drug combination of omeprazole, amoxicillin, and rifabutin in one capsule, RHB-105, from Michael E. De-Bakey Veterans Affairs Medical Center. This effectively eradicates Helicobacter pylori infection in adults.
• In July 2019, the USFDA approved Zydus Cadila’s Misoprostol tablets for treating stomach ulcers.

Report Scope